Sensome develops smart medical devices designed to provide real-time tissue characterization during endovascular procedures. The company’s lead product, Clotild, is a sensor-enabled guidewire intended to support decision-making in stroke treatment. Its approach focuses on enhancing procedural insight during minimally invasive vascular interventions. Sensome positions its technology within regulated clinical and interventional care contexts.

The technology integrates impedance-based microsensors into a standard guidewire form factor. As the guidewire navigates blood vessels, these sensors measure electrical properties of surrounding tissue and material. AI-driven analysis interprets these signals to characterize clot composition and vessel environment in real time. This information is intended to support clinicians in selecting appropriate tools and strategies during intervention.

Sensome targets acute ischemic stroke treatment, where rapid and informed intraoperative decisions can influence outcomes. The Clotild system is designed for use by interventional specialists within hospital settings. Its positioning reflects broader efforts to augment minimally invasive procedures with real-time sensing and intelligence to improve precision and procedural effectiveness.